Company Media

Travelan featured on The Not Old Better Show with Dr.Hailey Weerts - Research Scientist of Walter Reed Army Institute of Research. Dr Hailey is currently engaged in the investigation of immune responses to Shigella vaccines in pre-clinical/ human clinical

Immuron CEO - Dr Jerry Kanellos interviewed on the Red Chip Money Report, USA. Immuron: Developing Innovative Immunotherapy Therapies for Gut-Mediated Diseases

Biopharmaceutical company Immuron (ASX: IMC) is making significant territorial advances in its mission to develop and market a range of oral immunotherapeutics for the treatment of gut mediated pathogens.

The studies were designed to evaluate Travelan’s ability to neutralise pathogenic bacteria of interest, including Campylobacter, ETEC and Shigella bacterial infections. Travelan was shown to bind and was reactive to all strains of bacteria tested.

In January, Immuron (ASX:IMC) released a study of its Travelan tablets by the DOD which showed its was effective in preventing travellers diarrhoea in 180 strains of campylobacter.

There’s no arguing against the ‘breast is best’ mantra at long-standing Melbourne based biotech Immuron, which bases its therapeutics on the goodness of colostrum (the antibody-rich milk produced by mammals after birth).

Dual-listed early-stage biotech company Immuron (ASX: IMC) has revealed keenly anticipated results for its phase 2 non-alcoholic steatohepatitis (NASH) clinical study. The primary objective of the study was to evaluate the safety and efficacy of IMM-124E.

Shares in pharmaceutical company Immuron Limited surged by 80% when it announced promising results in testing its anti-inflammation drug. The Australian microbiome is developing and commercialising treatments for inflammatory and infectious diseases.

Top-line data showed treatment with IMM-124E (bovine colostrum) produced a statistically significant reduction in serum lipopolysaccharide (LPS) levels compared to placebo. LPS is associated with the progression of NASH.

Immuron Limited’s (ASX:IMC) (NASDAQ:IMRN) IMM-124E has demonstrated a statistically significant reduction in serum lipopolysaccharide (LPS) levels, a major factor in liver inflammation.

Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharide (LPS) levels compared to placebo; statistically significant reduction in mean serum ALT in patients with elevated pre-treatment AL

Today, IMC is setting a new standard as far as ‘positive developments’ go, topline results show significant improvement in liver injury and a significant reduction in blood levels of LPS — a known mediator of liver inflammation in patients with NASH.

Immuron Limited (ASX: IMC) said results of its IMM-124E phase II Non-Alcoholic Steatohepatitis (NASH) clinical study were positive. Results demonstrate excellent safety and tolerability; statistically significant reduction in serum endotoxin/liposaccharid

Immuron’s anti-NASH drug is IMM-124E, a colostrum-based compound. Colostrum is the first secretion (milk) from the mammary glands of cows post birth. Colostrum tends to be high in antibodies, although Immuron uses a very specific kind of colostrum achieve

Immuron is making progress on three clinical trials for IMM-124E, its nonalcoholic steatohepatitis and nonalcoholic fatty liver disease treatment. Here's what you should know.

Cookies and milk or cookies and colostrum? Immuron is targeting inflammatory bacteria in the gut with an engineered colostrum formulation, designed to prevent the liver damage that leads to NASH.